https://www.selleckchem.com/pr....oducts/lurbinectedin
Our results showed that the gene expression of SOCS1, SOCS3 and SHIP1 were increased after 6 months of therapy with M2000 in MS patients. Moreover, the serum level of IL-6 and TNF-α of patients declined when compared to baseline but this was not statistically significant. The results of this study demonstrated that M2000, with immunosuppressive properties, could upregulate SOCS1, SOCS3 and SHIP1 genes in patients with SPMS. This article is protected by copyright. All rights reserved.Although silver is an efficient antimicrobial an
Like
Comment
Share
